Lipitor (Atorvastatin): Pharmacology, Dosage, and Contraindications
This paper provides a concise pharmacological profile of Lipitor (atorvastatin), one of the most widely prescribed statin medications in the United States. It examines the drug's mechanism of action — specifically its inhibition of HMG-CoA reductase to reduce cholesterol synthesis — along with its clinical indications for atherosclerosis and cardiovascular disease prevention. The paper also addresses pharmacokinetic properties including absorption, bioavailability, distribution, and metabolism, as well as dosage guidelines and population-specific considerations such as differences in plasma concentration among elderly patients, females, and those with hepatic or renal disease.
- Introduction to Lipitor and Its Clinical Indications: Drug identity, statin class, and clinical indications
- Mechanism of Action and Hepatic Activity: HMG-CoA inhibition and hepatic elimination pathway
- Absorption, Dosage, and Metabolism: Oral dosing, absorption rate, and metabolic processing
- Bioavailability, Distribution, and Population Differences: Bioavailability percentages and patient population variation
- Contraindications and Special Populations: Hepatic disease, renal disease, and pregnancy warnings
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Integrates direct quotations from the prescribing information source to ground pharmacological claims in authoritative language, which is appropriate for a clinical overview.
- Progresses logically from indication and mechanism to pharmacokinetics and then to contraindications, mirroring the structure of a standard drug monograph.
- Briefly addresses population-level variation (elderly, female, hepatic, renal patients), showing awareness that pharmacokinetics differ across patient groups.
Key academic technique demonstrated
The paper demonstrates disciplined use of a single authoritative source — the RXList clinical pharmacology entry — by quoting selectively and then contextualizing each quoted passage with explanatory prose. This technique shows how to build an informative technical summary without over-relying on paraphrase or allowing quotations to stand without interpretation.
Structure breakdown
The paper is organized into five logical sections: (1) drug identity and clinical indications, (2) mechanism of action and hepatic elimination, (3) dosage and absorption/metabolism, (4) bioavailability and population-specific pharmacokinetics, and (5) contraindications including hepatic disease, renal disease, and pregnancy. Each section is concise, maintaining focus on pharmacological facts relevant to clinical use.
Introduction to Lipitor and Its Clinical Indications
Lipitor is a brand name of atorvastatin, one of the most commonly prescribed medications in the United States. Atorvastatin belongs to the statin family of drugs, which interact with specific enzymes in order to lower cholesterol in the body. Lipitor/atorvastatin inhibits HMG-CoA reductase, an enzyme that "converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols" like cholesterol ("Lipitor," n.d.).
Elevated plasma levels of total cholesterol — including both LDL-cholesterol (LDL-C) and HDL — as well as elevated levels of apolipoprotein B (apo B), are known precursors and risk factors in human atherosclerosis and cardiovascular disease. By reducing the amount of cholesterol in plasma and in the liver, the drug helps to prevent atherosclerosis and cardiovascular disease. Lipitor is effective in addressing elevated cholesterol due to hereditary hypercholesterolemia as well as nonfamilial types. It is indicated for patients with increased risk of myocardial infarction, stroke, and angina.
Mechanism of Action and Hepatic Activity
The drug is primarily active in the liver, which is the primary site of cholesterol synthesis ("Lipitor," n.d.). After metabolism in the liver, Lipitor and its metabolites are eliminated in bile. Very little of the drug is eliminated in urine. The "mean plasma elimination half-life of Lipitor in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites" ("Lipitor," n.d.). Ideally, Lipitor is an adjunct to diet, but it can also be effective for patients whose cholesterol levels do not respond adequately to dietary changes.
Absorption, Dosage, and Metabolism
Lipitor is taken orally and is rapidly absorbed; "maximum plasma concentrations occur within 1 to 2 hours" ("Lipitor," n.d.). The starting dose is 10–20 mg taken once per day, but the drug can be prescribed at up to 80 mg per day depending on the patient's response. Lipitor can be taken with or without food; food only slightly inhibits the rate of absorption but does not affect the overall effectiveness of the drug in LDL-C reduction ("Lipitor," n.d.).
Metabolism of Lipitor is rapid and relatively thorough, as it is "extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products" ("Lipitor," n.d.). The drug works by "increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL" ("Lipitor," n.d.).
Reference
"Lipitor." (n.d.). RXList. Retrieved from http://www.rxlist.com/lipitor-drug/clinical-pharmacology.htm
Create your account
Always verify citation format against your institution’s current style guide requirements.